The current landscape of treatment options for venous thromboembolism: a focus on novel oral anticoagulants

References

• Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e419-94S
   Web of Science ®Google Scholar
• Nicolaides A, Hull RD, Fareed J. Diagnosis and anticoagulant treatment. Clin Appl Thromb Hemost 2013;19:187-98
   PubMed Web of Science ®Google Scholar
• Hirsh J, Raschke R, Warkentin TE, et al. Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1995;108(4 Suppl):258-75S
   Web of Science ®Google Scholar
• Garcia DA, Baglin TP, Weitz JI, et al. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e24-43S
   Web of Science ®Google Scholar
• Hull RD, Raskob GE, Brant RF, et al. The importance of initial heparin treatment on long-term clinical outcomes of antithrombotic therapy. The emerging theme of delayed recurrence. Arch Intern Med 1997;157:2317-21
   PubMed Web of Science ®Google Scholar
• Smith SB, Geske JB, Maguire JM, et al. Early anticoagulation is associated with reduced mortality for acute pulmonary embolism. Chest 2010;137:1382-90
   PubMed Web of Science ®Google Scholar
• Rydberg EJ, Westfall JM, Nicholas RA. Low-molecular-weight heparin in preventing and treating DVT. Am Fam Physician 1999;59:1607-12
   PubMed Web of Science ®Google Scholar
• Hull RD, Marder VJ, Mah AF, et al. Quantitative assessment of thrombus burden predicts the outcome of treatment for venous thrombosis: a systematic review. Am J Med 2005;118:456-64
   PubMed Web of Science ®Google Scholar
• Hull RD, Pineo GF, Brant RF, et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 2006;119:1062-72
   PubMed Web of Science ®Google Scholar
• Hull RD, Townshend G. Long-term treatment of deep-vein thrombosis with low-molecular-weight heparin: an update of the evidence. Thromb Haemost 2013;110:14-22
   PubMed Web of Science ®Google Scholar
• Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349:146-53
   PubMed Web of Science ®Google Scholar
• Hull RD, Pineo GF, Brant R, et al. Home therapy of venous thrombosis with long-term LMWH versus usual care: patient satisfaction and post-thrombotic syndrome. Am J Med 2009;122:762-69 e3
   PubMed Web of Science ®Google Scholar
• Hull RD, Liang J, Townshend G. Long-term low-molecular-weight heparin and the post-thrombotic syndrome: a systematic review. Am J Med 2011;124:756-65
   PubMed Web of Science ®Google Scholar
• Nicolaides A, Hull RD, Fareed J, et al. Prevention of postthrombotic syndrome. Clin Appl Thromb Hemost 2013;19:213-15
   PubMed Web of Science ®Google Scholar
• Bergqvist D. Review of fondaparinux sodium injection for the prevention of venous thromboembolism in patients undergoing surgery. Vasc Health Risk Manag 2006;2:365-70
   PubMedGoogle Scholar
• Burch M, Cooper B. Fondaparinux-associated heparin-induced thrombocytopenia. Proc (Bayl Univ Med Cent) 2012;25:13-15
   PubMedGoogle Scholar
• Ageno W, Gallus AS, Wittkowsky A, et al. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e44-88S
   Web of Science ®Google Scholar
• Weitz JI. Factor Xa and thrombin as targets for new oral anticoagulants. Thromb Res 2011;127(Suppl 2):S5-12
   PubMed Web of Science ®Google Scholar
• Erkens PM, ten Cate H, Buller HR, Prins MH. Benchmark for time in therapeutic range in venous thromboembolism: a systematic review and meta-analysis. PLoS One 2012;7:e42269
   PubMed Web of Science ®Google Scholar
• Xarelto (rivaroxaban) tablets. Full prescribing information. Titusville, NJ, USA: Janssen Pharmaceutical Inc., 2014. Available at: https://www.xareltohcp.com. [Last accessed 15 June 2014]
   Google Scholar
• Pradaxa (dabigatran etexilate mesylate). Full prescribing information. Ridgefield, CT, USA: Boehringer Ingelheim Pharmaceuticals Inc., 2014 Available at: http://www.pradaxapro.com. [Last accessed 15 June 2014]
   Google Scholar
• Boehringer Ingelheim. Pradaxa gains EU approval for treatment and prevention of recurrence of deep vein thrombosis and pulmonary embolism. Available at: http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2014/06_june_2014_dabigatranetexilate.html [Last accessed 11 August 2014]
   Google Scholar
• Stangier J, Rathgen K, Stahle H, et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007;64:292-303
   PubMed Web of Science ®Google Scholar
• Di Nisio M, Middeldorp S, Buller HR. Direct thrombin inhibitors. N Engl J Med 2005;353:1028-40
   PubMed Web of Science ®Google Scholar
• Ansell J. Factor Xa or thrombin: is factor Xa a better target? J Thromb Haemost 2007;5(Suppl 1):60-4
   PubMed Web of Science ®Google Scholar
• Samama MM. The mechanism of action of rivaroxaban – an oral, direct Factor Xa inhibitor – compared with other anticoagulants. Thromb Res 2011;127:497-504
   PubMed Web of Science ®Google Scholar
• Frost C, Wang J, Nepal S, et al. Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol 2013;75:476-87
   PubMed Web of Science ®Google Scholar
• Kubitza D, Becka M, Wensing G, et al. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 – an oral, direct Factor Xa inhibitor – after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 2005;61:873-80
   PubMed Web of Science ®Google Scholar
• Ogata K, Mendell-Harary J, Tachibana M, et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol 2010;50:743-53
   PubMed Web of Science ®Google Scholar
• Blech S, Ebner T, Ludwig-Schwellinger E, et al. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 2008;36:386-99
   PubMed Web of Science ®Google Scholar
• Weinz C, Schwarz T, Kubitza D, et al. Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans. Drug Metab Dispos 2009;37:1056-64
   PubMed Web of Science ®Google Scholar
• Bathala MS, Masumoto H, Oguma T, et al. Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor xa inhibitor, in humans. Drug Metab Dispos 2012;40:2250-5
   PubMed Web of Science ®Google Scholar
• Raghavan N, Frost CE, Yu Z, et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos 2009;37:74-81
   PubMed Web of Science ®Google Scholar
• Mendell J, Zahir H, Matsushima N, et al. Drug–drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor. Am J Cardiovasc Drugs 2013;13:331-42
   PubMed Web of Science ®Google Scholar
• Stampfuss J, Kubitza D, Becka M, Mueck W. The effect of food on the absorption and pharmacokinetics of rivaroxaban. Int J Clin Pharmacol Ther 2013;51:549-61
   PubMed Web of Science ®Google Scholar
• Matsushima N, Lee F, Sato T, et al. Bioavailability and safety of the factor Xa inhibitor edoxaban and the effects of quinidine in healthy subjects. Clin Pharm Drug Dev 2013;2:358-66
   PubMed Web of Science ®Google Scholar
• Mendell J, Chen S, He L, et al. The effect of rifampin on the pharmacokinetics (PK) and pharmacodynamics (PD) of edoxaban in healthy subjects. J Thromb Haemost 2014;12(Suppl1):17
   Web of Science ®Google Scholar
• Wessler JD, Grip LT, Mendell J, Giugliano RP. The P-glycoprotein transport system and cardiovascular drugs. J Am Coll Cardiol 2013;61:2495-502
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Available at: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm#inhibitors [Last accessed 11 August 2014]
   Google Scholar
• Stangier J, Rathgen K, Stahle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 2010;49:259-68
   PubMed Web of Science ®Google Scholar
• Kubitza D, Becka M, Zuehlsdorf M, Mueck W. Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. J Clin Pharmacol 2006;46:549-58
   PubMed Web of Science ®Google Scholar
• Gnoth MJ, Buetehorn U, Muenster U, et al. In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban. J Pharmacol Exp Ther 2011;338:372-80
   PubMed Web of Science ®Google Scholar
• Mueck W, Kubitza D, Becka M. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. Br J Clin Pharmacol 2013;76:455-66
   PubMed Web of Science ®Google Scholar
• Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009;361:2342-52
   PubMed Web of Science ®Google Scholar
• Schulman S, Kakkar AK, Goldhaber SZ, et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 2014;129:764-72
   PubMed Web of Science ®Google Scholar
• The EINSTEIN-DVT Investigators, Bauersachs R, Berkowitz SD, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363:2499-510
   PubMed Web of Science ®Google Scholar
• The EINSTEIN-PE Investigators, Buller HR, Prins MH, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012;366:1287-97
   PubMed Web of Science ®Google Scholar
• Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013;369:799-808
   PubMed Web of Science ®Google Scholar
• The Hokusai-VTE Investigators, Buller HR, Decousus H, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013;369:1406-15
   PubMed Web of Science ®Google Scholar
• Raskob G, Buller H, Prins M, et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-VTE study. J Thromb Haemost 2013;11:1287-94
   PubMed Web of Science ®Google Scholar
• Schulman S, Kearon C, Kakkar AK, et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 2013;368:709-18
   PubMed Web of Science ®Google Scholar
• Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013;368:699-708
   PubMed Web of Science ®Google Scholar
• Lefebvre P, Coleman CI, Bookhart BK, et al. Cost-effectiveness of rivaroxaban compared with enoxaparin plus a vitamin K antagonist for the treatment of venous thromboembolism. J Med Econ 2014;17:52-64
   PubMedGoogle Scholar
• Moia M, Mantovani LG, Carpenedo M, et al. Patient preferences and willingness to pay for different options of anticoagulant therapy. Intern Emerg Med 2013;8:237-43
   PubMed Web of Science ®Google Scholar
• Bamber L, Wang MY, Prins MH, et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis. Thromb Haemost 2013;110:732-41
   PubMed Web of Science ®Google Scholar
• Garcia D, Barrett YC, Ramacciotti E, Weitz JI. Laboratory assessment of the anticoagulant effects of the next generation of oral anticoagulants. J Thromb Haemost 2013;11:245-52
   PubMed Web of Science ®Google Scholar
• Kaatz S, Kouides PA, Garcia DA, et al. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol 2012;87(Suppl 1):S141-5
   PubMed Web of Science ®Google Scholar
• Eerenberg ES, Kamphuisen PW, Sijpkens MK, et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011;124:1573-9
   PubMed Web of Science ®Google Scholar
• Escolar G, Arrelano-Rodrigo E, Reverter JC. Coagulation factor concentrates restore alterations in hemostasis induced by a high dose of apixaban: studies in vitro with circulating human blood. Blood 2012;120:2263
   Web of Science ®Google Scholar
• Godier A, Martin A-C, Samama C, et al. Reversal of anticoagulant effects of apixaban with non-specific prohaemostatic agents: an in vitro study. J Thromb Haemost 2013;11(Suppl s2):826
   PubMedGoogle Scholar
• Halim A-B, Li Y, Stein E, Mendell J. Low concentrations of rhFVIIa or FEIBA significantly and rapidly reverse the anticoagulant effects of supratherapeutic edoxaban. Blood 2011;118:1252
   Web of Science ®Google Scholar
• Khoo TL, Weatherburn C, Kershaw G, et al. The use of FEIBA in the correction of coagulation abnormalities induced by dabigatran. Int J Lab Hematol 2013;35:222-4
   PubMed Web of Science ®Google Scholar
• Marlu R, Hodaj E, Paris A, et al. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost 2012;108:217-24
   PubMed Web of Science ®Google Scholar
• Perzborn E, Heitmeier S, Laux V, Buchmüller A. Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro. Thromb Res 2014;133:671-81
   PubMed Web of Science ®Google Scholar
• Kiraly A, Lyden A, Periyanayagam U, et al. Management of hemorrhage complicated by novel oral anticoagulants in the emergency department: case report from the northwestern emergency medicine residency. Am J Ther 2013;20:300-6
   PubMed Web of Science ®Google Scholar
• Lillo-Le Louet A, Wolf M, Soufir L, et al. Life-threatening bleeding in four patients with an unusual excessive response to dabigatran: implications for emergency surgery and resuscitation. Thromb Haemost 2012;108:108583-5
   Web of Science ®Google Scholar
• Crowther M, Marthur V, Kitt M, et al. A phase 2 randomized, double-blind, placebo-controlled trial demonstrating reversal of rivaroxaban-induced anticoagulation in healthy subjects by andexanet alfa (PRT064445), an antidote for Fxa inhibitors. Blood 2013;122:3636
   Web of Science ®Google Scholar
• Bakhru S, Laulicht B, Jiang X, et al. A synthetic small molecule antidote for anticoagulants. Eur Heart J 2013;34:188-9, Abstract 1078
   Web of Science ®Google Scholar
• Laulicht B, Bakhru S, Lee C. Small molecule antidote for anticoagulants. Circulation 2012;126:A11395
   Web of Science ®Google Scholar
• Glund S, Stangier J, Schmol M, et al. A specific antidote for dabigatran: immediate, complete and sustained reversal of dabigatran induced anticoagulation in healthy male volunteers. Circulation 2013;128:Abstract 17765
   Web of Science ®Google Scholar
• Southworth MR, Reichman ME, Unger EF. Dabigatran and postmarketing reports of bleeding. N Engl J Med 2013;368:1272-4
   PubMed Web of Science ®Google Scholar
• Institute for Safe Medication Practices. ISMP Quarter Watch 2012 Q2. Monitoring FDA MedWatch reports. Available at: http://www.ismp.org/quarterwatch/pdfs/2012Q2.pdf [Last accessed 11 August 2014]
   Google Scholar
• Pfeilschifter W, Luger S, Brunkhorst R, et al. The gap between trial data and clinical practice – an analysis of case reports on bleeding complications occurring under dabigatran and rivaroxaban anticoagulation. Cerebrovasc Dis 2013;36:115-19
   PubMed Web of Science ®Google Scholar
• FDA Drug Safety Communication: FDA study of Medicare patients finds risks lower for stroke and death but higher for gastrointestinal bleeding with Pradaxa (dabigatran) compared to warfarin. Available at: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM397606.pdf [Last accessed 11 August 2014]
   Google Scholar
• Kuroda Y, Hirayama C, Hotoda H, et al. Postmarketing safety experience with edoxaban in Japan for thromboprophylaxis following major orthopedic surgery. Vasc Health Risk Manag 2013;9:593-8
   PubMedGoogle Scholar